DelveInsight has launched a new report on “Fibrodysplasia ossificans progressiva (FOP) Market Insights, Epidemiology, and Market Forecast-2032”. 

DelveInsight’s “Fibrodysplasia ossificans progressiva (FOP) – Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fibrodysplasia ossificans progressiva (FOP), historical and forecasted epidemiology as well as the Fibrodysplasia ossificans progressiva (FOP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Fibrodysplasia ossificans progressiva (FOP) Market Report:

• According to a study by Moira et al. (2021), the prevalence of FOP is approximately 0.65 per million in North America 
• According to the European Conference on Rare Diseases, FOP has a prevalence rate of 0.08 per 100,000 people 
• According to a study by Robert J et al. (2021), most individuals living with FOP (87%) were alive in the first five decades (0-49 years of age) of their lives 
• According to Robert et al. (2021), an estimated minimum prevalence is 0.88 per million individuals (1 in 1.14 million people) in the United States 
• As per the data collected from various studies, the prevalence of FOP is more in females than in males 

Request a sample for the Report: https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-market

Key benefits of the report:

1. Fibrodysplasia ossificans progressiva (FOP) market report covers a descriptive overview and comprehensive insight of the Fibrodysplasia ossificans progressiva (FOP) Epidemiology and Fibrodysplasia ossificans progressiva (FOP)  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Fibrodysplasia ossificans progressiva (FOP) market report provides insights on the current and emerging therapies.
3. Fibrodysplasia ossificans progressiva (FOP) market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Fibrodysplasia ossificans progressiva (FOP) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fibrodysplasia ossificans progressiva (FOP) market.

Epidemiology Segmentation:

• Total Prevalent cases of Fibrodysplasia Ossificans Progressiva in the 7MM [2019–2032]
• Total Diagnosed Prevalent cases of Fibrodysplasia Ossificans Progressiva in the 7MM [2019–2032]
• Gender-specific cases of Fibrodysplasia Ossificans Progressiva [2019–2032]
• Age-specific cases of Fibrodysplasia Ossificans Progressiva [2019–2032]

Got queries? Click here to know more about the Fibrodysplasia ossificans progressiva (FOP) Market Landscape 

Fibrodysplasia ossificans progressiva (FOP) Overview: 

Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. Specifically, this disorder causes the body’s skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible. 

FOP is caused by a mutation in the ACVR1 gene. This gene is involved in growth and development of bones. The mutation allows them to grow unchecked. The gene can be inherited from one parent, but in most cases of FOP, it’s a new mutation in a person with no family history of the disease. 

Fibrodysplasia ossificans progressiva (FOP) Symptoms:

The symptoms of Fibrodysplasia ossificans progressiva include –

• Repeated episodes of muscle swelling and inflammation
• Difficulty in speaking and eating
• Malformed big toes

Fibrodysplasia ossificans progressiva (FOP) Market  

The dynamics of the Fibrodysplasia ossificans progressiva (FOP) market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as IPN60130, Garetosmab, and others during the forecasted period 2019-2032. 

Learn more by requesting for sample @Fibrodysplasia ossificans progressiva (FOP) Market Landscape  

Fibrodysplasia ossificans progressiva (FOP) Pipeline Therapies:

• IPN60130
• Garetosmab
• Palovarotene
• REGN2477 

Fibrodysplasia ossificans progressiva (FOP) Pipeline Key Companies:

• Ipsen
• Incyte Corporation
•  Regeneron Pharmaceuticals
• Clementia Pharmaceuticals

Table of Contents 

1. Fibrodysplasia ossificans progressiva (FOP) Market Report Introduction

2. Executive Summary

3. SWOT analysis

4. Fibrodysplasia ossificans progressiva (FOP) Patient Share (%) Overview at a Glance

5. Fibrodysplasia ossificans progressiva (FOP) Market Overview at a Glance

6. Fibrodysplasia ossificans progressiva (FOP) Disease Background and Overview

7. Fibrodysplasia ossificans progressiva (FOP) Epidemiology and Patient Population

8. Country-Specific Patient Population of Fibrodysplasia ossificans progressiva (FOP) 

9. Fibrodysplasia ossificans progressiva (FOP) Current Treatment and Medical Practices

10. Fibrodysplasia ossificans progressiva (FOP) Unmet Needs

11. Fibrodysplasia ossificans progressiva (FOP) Emerging Therapies

12. Fibrodysplasia ossificans progressiva (FOP) Market Outlook

13. Country-Wise Fibrodysplasia ossificans progressiva (FOP) Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Fibrodysplasia ossificans progressiva (FOP) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Fibrodysplasia ossificans progressiva (FOP) Market Outlook 2032

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com